Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Healthy Participants 5Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Solid Tumor, Adult 2Healthy Volunteers 2Breast Neoplasms 2cMET-dysregulated Advanced Solid Tumors 1TP53 Y220C Mutation 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Pain 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Healthy Adult Participants 1Healthy 1Drug-drug Interaction,SHR3680 1Colorectal Neoplasms 1Chronic Cough 1Carcinoma, Squamous Cell 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Advanced Non-small Cell Lung Cancer 1

Interventions

Rosuvastatin Calcium 2technetium 99m HYNIC-duramycin 1eltrombopag 1darolutamide 1Cell Death 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Healthy Volunteers × Rosuvastatin Calcium × Clear all
NCT04542382 2025-03-30

BCRPmarker

University of California, San Francisco

Phase 1 Completed
11 enrolled

Healthy Volunteers

NCT02671097 2016-09-08

Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

Bayer

Phase 1 Completed
30 enrolled

Healthy Volunteers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡